Lissoni P, Rovelli F, Tisi E, Brivio F, Ardizzoia A, Barni S, Tancini G, Saudelli M, Cesana E, Viganò M G
Division of Oncological Radiotherapy, San Gerardo Hospital, Monza, Milano, Italy.
J Biol Regul Homeost Agents. 1995 Oct-Dec;9(4):146-9.
At present, it is known that there are two main mechanisms responsible for cancer-related immunosuppression, mediated by macrophages and by TH2 lymphocytes. The relation existing between macrophage- and TH2-mediated immunosuppression still remains to be understood. The present study was performed in an attempt to establish which is the correlation existing in cancer patients between IL-10 and neopterin levels, which reflect TH2- and macrophage-mediated suppressive events, respectively. The study included 40 solid tumor patients and 60 healthy subjects as controls. Serum concentrations of neopterin and IL-10 were measured by the RIA method and by an immuno-enzymetric assay, respectively. Because of its possible production both by TH2 and macrophages, serum levels of IL-6 were also determined. Neopterin, IL-10 IL-6 mean concentrations were significantly higher in cancer patients than in controls. Mean values of both neopterin and IL-6 were significantly higher in metastatic patients than in those with locally limited disease. IL-10 mean levels were also significantly higher in patients with metastatic disease. IL-6 levels were significantly correlated with those of neopterin, whereas no correlation was found between neopterin and IL-10 values. This preliminary study would suggest that macrophage- and TH2-mediated immunosuppression may occur independently in solid tumors, and that it becomes more evident with disease progression.
目前已知,癌症相关的免疫抑制主要由巨噬细胞和TH2淋巴细胞介导的两种机制引起。巨噬细胞介导的免疫抑制与TH2介导的免疫抑制之间的关系仍有待了解。本研究旨在确定癌症患者中分别反映TH2和巨噬细胞介导的抑制事件的IL-10水平与新蝶呤水平之间的相关性。该研究纳入了40例实体瘤患者和60例健康受试者作为对照。分别采用放射免疫分析法(RIA)和免疫酶分析法测定血清中新蝶呤和IL-10的浓度。由于IL-6可能由TH2和巨噬细胞产生,因此也测定了血清IL-6水平。癌症患者血清中新蝶呤、IL-10和IL-6的平均浓度显著高于对照组。转移性患者中新蝶呤和IL-6的平均值显著高于局部局限性疾病患者。转移性疾病患者的IL-10平均水平也显著更高。IL-6水平与新蝶呤水平显著相关,而新蝶呤与IL-10值之间未发现相关性。这项初步研究表明,巨噬细胞和TH2介导的免疫抑制可能在实体瘤中独立发生,并且随着疾病进展变得更加明显。